Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FAST alone Clear all
Active, not recruiting Not applicable Interventional

A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)

NCT04820036
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Function, Obesity, Liver Fibroses
Interventions
Insulin Resistance, Quality of Life Assessment, Liver Function Test, Radiologic features of NASH, Serologic features of NASH
Diagnostic Test · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

NCT05002231
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Losmapimod 15 mg oral tablet, Losmapimod two 7.5 mg oral tablets, Losmapimod one 15 mg oral tablet
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 22, 2026, 9:38 AM EDT
Terminated Phase 1 Interventional Results available

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

NCT03894540
View directory record Official record
Conditions
Solid Tumor
Interventions
IPN60090, pembrolizumab, paclitaxel, IPN60090 single administration
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg

NCT00648791
View directory record Official record
Conditions
Healthy
Interventions
Finasteride Tablets 5 mg, Proscar Tablets 5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Not applicable Interventional

Default Bulk Ordering and Text Messaging to Enhance Outreach for Lipid Screening (Missing Lipids)

NCT05724615
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Outreach + Bulk ordering, Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
20 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg

NCT00647816
View directory record Official record
Conditions
Healthy
Interventions
Propranolol Hydrochloride Extended-Release Capsules 160 mg, Inderal® LA Capsules 160 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Not applicable Interventional

SDRM® vs. Collagen for Diabetic Foot Ulcers

NCT05883098
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot, Wound Heal
Interventions
Wound debridement, Wound closure matrix application
Procedure · Device
Lead sponsor
Polymedics Innovations Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Circleville, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

NCT03828084
View directory record Official record
Conditions
Healthy
Interventions
Decitabine
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg

NCT00650065
View directory record Official record
Conditions
Healthy
Interventions
Cetirizine HCl Tablets 10 mg, Zyrtec® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

NCT00662857
View directory record Official record
Conditions
Diabetes Mellitus: Type 1
Interventions
Technosphere Insulin® Inhalation Powder, RAA Population
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg

NCT00650195
View directory record Official record
Conditions
Healthy
Interventions
Metolazone Tablets 10 mg, Zaroloxyn® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

NCT06094712
View directory record Official record
Conditions
Healthy
Interventions
CORT125134
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Not applicable Interventional Results available

Time Restricted Eating for Weight Loss Maintenance

NCT05742165
View directory record Official record
Conditions
Obesity
Interventions
Time Restricted Eating (TRE)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

NCT05138653
View directory record Official record
Conditions
Healthy Participants
Interventions
CVL-354, Placebo
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

NCT03555617
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
TD-1473, Itraconazole
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

NCT03228433
View directory record Official record
Conditions
Healthy Participants
Interventions
TAK-418, TAK-418 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 22, 2026, 9:38 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Motivational Refinements for Facilitating Reinforcement Schedule Thinning

NCT05790668
View directory record Official record
Conditions
Decreasing Destructive Behavior, Increasing Functional Communicative Behavior
Interventions
Traditional Schedule Thinning, PIA-Informed Schedule Thinning, PIA-Informed Schedule Thinning with Competing Stimuli
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
3 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey • Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Recruiting Not applicable Interventional

Tract Closure in PCNL

NCT07668817
View directory record Official record
Conditions
Nephrolithiasis
Interventions
Floseal, Surgicel, Surgiflo, Balloon Tamponade
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

NCT06945276
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558, Dabigatran, Itraconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional

Tisagenlecleucel In Primary CNS Lymphoma

NCT04134117
View directory record Official record
Conditions
Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma
Interventions
Tisagenlecleucel
Biological
Lead sponsor
Matthew J. Frigault, M.D.
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects

NCT02175238
View directory record Official record
Conditions
Healthy
Interventions
BI 691751 fasted, BI 691751 after high fat breakfast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

NCT01954238
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GCC-4401C, Rivaroxaban, Placebo
Drug
Lead sponsor
Green Cross Corporation
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Early Phase Clinical Unit _Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 22, 2026, 9:38 AM EDT
Not listed Not applicable Interventional

End-Tidal Oxygen for Intubation in the Emergency Department

NCT06578468
View directory record Official record
Conditions
Critical Illness, Hypoxia, Respiratory Failure
Interventions
End-tidal oxygen monitor
Device
Lead sponsor
Sydney Local Health District
Government
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Minneapolis, Minnesota • Albuquerque, New Mexico • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 9:38 AM EDT